220 related articles for article (PubMed ID: 37731264)
1. Peripheral blood inflammatory biomarkers dynamics reflect treatment response and predict prognosis in non-small cell lung cancer patients with neoadjuvant immunotherapy.
Huai Q; Luo C; Song P; Bie F; Bai G; Li Y; Liu Y; Chen X; Zhou B; Sun X; Guo W; Gao S
Cancer Sci; 2023 Dec; 114(12):4484-4498. PubMed ID: 37731264
[TBL] [Abstract][Full Text] [Related]
2. The predictive value of inflammatory biomarkers for major pathological response in non-small cell lung cancer patients receiving neoadjuvant chemoimmunotherapy and its association with the immune-related tumor microenvironment: a multi-center study.
Li C; Wu J; Jiang L; Zhang L; Huang J; Tian Y; Zhao Y; Liu X; Xia L; E H; Gao P; Hou L; Yang M; Ma M; Su C; Zhang H; Chen H; She Y; Xie D; Luo Q; Chen C
Cancer Immunol Immunother; 2023 Mar; 72(3):783-794. PubMed ID: 36056951
[TBL] [Abstract][Full Text] [Related]
3. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
[TBL] [Abstract][Full Text] [Related]
4. Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer.
Tong YS; Tan J; Zhou XL; Song YQ; Song YJ
J Transl Med; 2017 Oct; 15(1):221. PubMed ID: 29089030
[TBL] [Abstract][Full Text] [Related]
5. Systemic immune-inflammation index changes predict outcome in stage III non-small-cell lung cancer patients treated with concurrent chemoradiotherapy.
Huang T; Zhang H; Zhao Y; Li Y; Wang G; Zhang Y; Guo D; Ji S; Sun Z
Future Oncol; 2021 Jun; 17(17):2141-2149. PubMed ID: 33635094
[No Abstract] [Full Text] [Related]
6. Tertiary lymphoid structures combined with biomarkers of inflammation are associated with the efficacy of neoadjuvant immunochemotherapy in resectable non-small cell lung cancer: A retrospective study.
Xu F; Zhu H; Xiong D; Wang K; Dong Y; Li L; Yuan S
Thorac Cancer; 2024 Jan; 15(2):172-181. PubMed ID: 38057283
[TBL] [Abstract][Full Text] [Related]
7. Preoperative systemic immune-inflammation index predicts prognosis and guides clinical treatment in patients with non-small cell lung cancer.
Yan X; Li G
Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32175568
[TBL] [Abstract][Full Text] [Related]
8. The predictive role of hematologic markers in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy: a retrospective cohort study.
Liu W; Ren S; Yang L; Xiao Y; Zeng C; Chen C; Wu F; Hu Y
Int J Surg; 2023 Nov; 109(11):3519-3526. PubMed ID: 37578441
[TBL] [Abstract][Full Text] [Related]
9. Clinical Utility of Inflammatory and Nutritious Index as Therapeutic Prediction of Nivolumab plus Ipilimumab in Advanced Non-Small Cell Lung Cancer.
Yamaguchi O; Kaira K; Imai H; Mouri A; Shiono A; Miura Y; Hashimoto K; Kobayashi K; Kagamu H
Oncology; 2024; 102(3):271-282. PubMed ID: 37725914
[TBL] [Abstract][Full Text] [Related]
10. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
[TBL] [Abstract][Full Text] [Related]
11. Combined inflammatory parameters and tertiary lymphoid structure predict prognosis in patients with resectable non-small cell lung cancer treated with neoadjuvant chemoimmunotherapy.
Xu F; Zhu H; Dong Y; Li L; Liu N; Yuan S
Front Immunol; 2023; 14():1244256. PubMed ID: 38155965
[TBL] [Abstract][Full Text] [Related]
12. Utility of prognostic nutritional index and systemic immune-inflammation index in oral cancer treatment.
Kubota K; Ito R; Narita N; Tanaka Y; Furudate K; Akiyama N; Chih CH; Komatsu S; Kobayashi W
BMC Cancer; 2022 Apr; 22(1):368. PubMed ID: 35392843
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of immunotherapy-induced inflammation indexes: dynamic changes in patients with nasopharyngeal carcinoma receiving immune checkpoint inhibitors.
Cao J; Chen Q; Bai X; Liu L; Ma W; Lin C; Lu F; Zhou T; Zhan J; Huang Y; Yang Y; Luo F; Zhao H
Ann Med; 2023; 55(2):2280002. PubMed ID: 38065623
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of preoperative hematological markers in patients with glioblastoma multiforme and construction of random survival forest model.
Duan X; Yang B; Zhao C; Tie B; Cao L; Gao Y
BMC Cancer; 2023 May; 23(1):432. PubMed ID: 37173662
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of immune inflammation biomarkers in predicting survival and radiosensitivity in patients with non-small-cell lung cancer treated with chemoradiotherapy.
Delikgoz Soykut E; Kemal Y; Karacin C; Karaoglanoglu O; Kurt M; Aytac Arslan S
J Med Imaging Radiat Oncol; 2022 Feb; 66(1):146-157. PubMed ID: 34632714
[TBL] [Abstract][Full Text] [Related]
16. Prognostic roles of hematological indicators for the efficacy and prognosis of immune checkpoint inhibitors in patients with advanced tumors: a retrospective cohort study.
Zheng F; Meng Q; Zhang L; Chen J; Zhao L; Zhou Z; Liu Y
World J Surg Oncol; 2023 Jul; 21(1):198. PubMed ID: 37420219
[TBL] [Abstract][Full Text] [Related]
17. Novel peripheral blood parameters as predictors of neoadjuvant chemotherapy response in breast cancer.
Yang G; Liu P; Zheng L; Zeng J
Front Surg; 2022; 9():1004687. PubMed ID: 36406359
[TBL] [Abstract][Full Text] [Related]
18. [The prognostic value of preoperative peripheral blood inflammatory biomarkers for intrahepatic cholangiocarcinoma after radical resection].
Li Q; Zhang R; Fu JL; Zhang J; Su JB; Jin ZC; Chen C; Zhang D; Geng ZM
Zhonghua Zhong Liu Za Zhi; 2022 Nov; 44(11):1194-1201. PubMed ID: 36380668
[No Abstract] [Full Text] [Related]
19. High systemic immune-inflammation index predicts poor prognosis in advanced lung adenocarcinoma patients treated with EGFR-TKIs.
Deng C; Zhang N; Wang Y; Jiang S; Lu M; Huang Y; Ma J; Hu C; Hou T
Medicine (Baltimore); 2019 Aug; 98(33):e16875. PubMed ID: 31415428
[TBL] [Abstract][Full Text] [Related]
20. Systemic immune-inflammation index (SII) is useful to predict survival outcomes in patients with surgically resected non-small cell lung cancer.
Guo W; Cai S; Zhang F; Shao F; Zhang G; Zhou Y; Zhao L; Tan F; Gao S; He J
Thorac Cancer; 2019 Apr; 10(4):761-768. PubMed ID: 30734516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
